Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated

Cristina Cabrera-López, Gemma Bullich, Teresa Martí, Violeta Català, Jose Ballarín, John J. Bissler, Peter C Harris, Elisabet Ars, Roser Torra

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Mutations in TSC1 or TSC2 cause the tuberous sclerosis complex (TSC), while mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 lays immediately adjacent to TSC2 and deletions involving both genes, the PKD1/TSC2 contiguous gene syndrome (CGS), are characterized by severe ADPKD, plus TSC. mTOR inhibitors have proven effective in reducing angiomyolipoma (AML) in TSC and total kidney volume in ADPKD but without a positive effect on renal function. Methods and results: We describe a patient with independent truncating PKD1 and TSC2 mutations who has the expected phenotype for both diseases independently instead of the severe one described in PKD1/TSC2-CGS. Treatment with mTOR inhibitors reduced the AML and kidney volume for 2 years but thereafter they resumed growth; no positive effect on renal function was seen throughout. This is the first case addressing the response to mTOR treatment when independent truncating mutations in PKD1 and TSC2 are present. Conclusions: This case reveals that although PKD1 and TSC2 are adjacent genes and there is likely cross-talk between the PKD1 and TSC2 signalling pathways regulating mTOR, having independent TSC2 and PKD1 mutations can give rise to a milder kidney phenotype than is typical in PKD1/TSC2-CGS cases. A short-term beneficial effect of mTOR inhibition on AML and total kidney volume was not reflected in improved renal function.

Original languageEnglish (US)
Article number39
JournalBMC Medical Genetics
Volume16
Issue number1
DOIs
StatePublished - Jun 17 2015

Fingerprint

Kidney
Angiomyolipoma
Autosomal Dominant Polycystic Kidney
Tuberous Sclerosis
Mutation
Genes
Phenotype
Therapeutics
Growth

Keywords

  • ADPKD
  • mTOR inhibitors
  • Polycystic
  • Tuberous sclerosis complex

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Medicine(all)

Cite this

Cabrera-López, C., Bullich, G., Martí, T., Català, V., Ballarín, J., Bissler, J. J., ... Torra, R. (2015). Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Medical Genetics, 16(1), [39]. https://doi.org/10.1186/s12881-015-0185-y

Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. / Cabrera-López, Cristina; Bullich, Gemma; Martí, Teresa; Català, Violeta; Ballarín, Jose; Bissler, John J.; Harris, Peter C; Ars, Elisabet; Torra, Roser.

In: BMC Medical Genetics, Vol. 16, No. 1, 39, 17.06.2015.

Research output: Contribution to journalArticle

Cabrera-López, C, Bullich, G, Martí, T, Català, V, Ballarín, J, Bissler, JJ, Harris, PC, Ars, E & Torra, R 2015, 'Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated', BMC Medical Genetics, vol. 16, no. 1, 39. https://doi.org/10.1186/s12881-015-0185-y
Cabrera-López C, Bullich G, Martí T, Català V, Ballarín J, Bissler JJ et al. Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Medical Genetics. 2015 Jun 17;16(1). 39. https://doi.org/10.1186/s12881-015-0185-y
Cabrera-López, Cristina ; Bullich, Gemma ; Martí, Teresa ; Català, Violeta ; Ballarín, Jose ; Bissler, John J. ; Harris, Peter C ; Ars, Elisabet ; Torra, Roser. / Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. In: BMC Medical Genetics. 2015 ; Vol. 16, No. 1.
@article{860b539c975f4461b0f3cdf5be35c7b7,
title = "Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated",
abstract = "Background: Mutations in TSC1 or TSC2 cause the tuberous sclerosis complex (TSC), while mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 lays immediately adjacent to TSC2 and deletions involving both genes, the PKD1/TSC2 contiguous gene syndrome (CGS), are characterized by severe ADPKD, plus TSC. mTOR inhibitors have proven effective in reducing angiomyolipoma (AML) in TSC and total kidney volume in ADPKD but without a positive effect on renal function. Methods and results: We describe a patient with independent truncating PKD1 and TSC2 mutations who has the expected phenotype for both diseases independently instead of the severe one described in PKD1/TSC2-CGS. Treatment with mTOR inhibitors reduced the AML and kidney volume for 2 years but thereafter they resumed growth; no positive effect on renal function was seen throughout. This is the first case addressing the response to mTOR treatment when independent truncating mutations in PKD1 and TSC2 are present. Conclusions: This case reveals that although PKD1 and TSC2 are adjacent genes and there is likely cross-talk between the PKD1 and TSC2 signalling pathways regulating mTOR, having independent TSC2 and PKD1 mutations can give rise to a milder kidney phenotype than is typical in PKD1/TSC2-CGS cases. A short-term beneficial effect of mTOR inhibition on AML and total kidney volume was not reflected in improved renal function.",
keywords = "ADPKD, mTOR inhibitors, Polycystic, Tuberous sclerosis complex",
author = "Cristina Cabrera-L{\'o}pez and Gemma Bullich and Teresa Mart{\'i} and Violeta Catal{\`a} and Jose Ballar{\'i}n and Bissler, {John J.} and Harris, {Peter C} and Elisabet Ars and Roser Torra",
year = "2015",
month = "6",
day = "17",
doi = "10.1186/s12881-015-0185-y",
language = "English (US)",
volume = "16",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated

AU - Cabrera-López, Cristina

AU - Bullich, Gemma

AU - Martí, Teresa

AU - Català, Violeta

AU - Ballarín, Jose

AU - Bissler, John J.

AU - Harris, Peter C

AU - Ars, Elisabet

AU - Torra, Roser

PY - 2015/6/17

Y1 - 2015/6/17

N2 - Background: Mutations in TSC1 or TSC2 cause the tuberous sclerosis complex (TSC), while mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 lays immediately adjacent to TSC2 and deletions involving both genes, the PKD1/TSC2 contiguous gene syndrome (CGS), are characterized by severe ADPKD, plus TSC. mTOR inhibitors have proven effective in reducing angiomyolipoma (AML) in TSC and total kidney volume in ADPKD but without a positive effect on renal function. Methods and results: We describe a patient with independent truncating PKD1 and TSC2 mutations who has the expected phenotype for both diseases independently instead of the severe one described in PKD1/TSC2-CGS. Treatment with mTOR inhibitors reduced the AML and kidney volume for 2 years but thereafter they resumed growth; no positive effect on renal function was seen throughout. This is the first case addressing the response to mTOR treatment when independent truncating mutations in PKD1 and TSC2 are present. Conclusions: This case reveals that although PKD1 and TSC2 are adjacent genes and there is likely cross-talk between the PKD1 and TSC2 signalling pathways regulating mTOR, having independent TSC2 and PKD1 mutations can give rise to a milder kidney phenotype than is typical in PKD1/TSC2-CGS cases. A short-term beneficial effect of mTOR inhibition on AML and total kidney volume was not reflected in improved renal function.

AB - Background: Mutations in TSC1 or TSC2 cause the tuberous sclerosis complex (TSC), while mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 lays immediately adjacent to TSC2 and deletions involving both genes, the PKD1/TSC2 contiguous gene syndrome (CGS), are characterized by severe ADPKD, plus TSC. mTOR inhibitors have proven effective in reducing angiomyolipoma (AML) in TSC and total kidney volume in ADPKD but without a positive effect on renal function. Methods and results: We describe a patient with independent truncating PKD1 and TSC2 mutations who has the expected phenotype for both diseases independently instead of the severe one described in PKD1/TSC2-CGS. Treatment with mTOR inhibitors reduced the AML and kidney volume for 2 years but thereafter they resumed growth; no positive effect on renal function was seen throughout. This is the first case addressing the response to mTOR treatment when independent truncating mutations in PKD1 and TSC2 are present. Conclusions: This case reveals that although PKD1 and TSC2 are adjacent genes and there is likely cross-talk between the PKD1 and TSC2 signalling pathways regulating mTOR, having independent TSC2 and PKD1 mutations can give rise to a milder kidney phenotype than is typical in PKD1/TSC2-CGS cases. A short-term beneficial effect of mTOR inhibition on AML and total kidney volume was not reflected in improved renal function.

KW - ADPKD

KW - mTOR inhibitors

KW - Polycystic

KW - Tuberous sclerosis complex

UR - http://www.scopus.com/inward/record.url?scp=84934298178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934298178&partnerID=8YFLogxK

U2 - 10.1186/s12881-015-0185-y

DO - 10.1186/s12881-015-0185-y

M3 - Article

C2 - 26077033

AN - SCOPUS:84934298178

VL - 16

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

IS - 1

M1 - 39

ER -